CN101198596A - 作为hsp90抑制剂用于治疗增殖疾病的2-氨基-喹唑啉-5-酮 - Google Patents

作为hsp90抑制剂用于治疗增殖疾病的2-氨基-喹唑啉-5-酮 Download PDF

Info

Publication number
CN101198596A
CN101198596A CNA2006800212085A CN200680021208A CN101198596A CN 101198596 A CN101198596 A CN 101198596A CN A2006800212085 A CNA2006800212085 A CN A2006800212085A CN 200680021208 A CN200680021208 A CN 200680021208A CN 101198596 A CN101198596 A CN 101198596A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
methoxy
pyridin
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800212085A
Other languages
English (en)
Chinese (zh)
Inventor
T·D·马查朱斯基
Z·高
B·H·莱文
W·安托尼奥斯-麦克雷
C·R·贝拉马西纳
A·科斯泰尔思
B·M·道格翰
S·冯
T·亨德里克森
林晓东
C·麦克布莱德
M·麦克肯纳
A·C·里科
C·M·谢弗
X·M·王
Y·周
夏奕
K·G·门登豪尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of CN101198596A publication Critical patent/CN101198596A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2006800212085A 2005-04-14 2006-04-14 作为hsp90抑制剂用于治疗增殖疾病的2-氨基-喹唑啉-5-酮 Pending CN101198596A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67166205P 2005-04-14 2005-04-14
US60/671,662 2005-04-14

Publications (1)

Publication Number Publication Date
CN101198596A true CN101198596A (zh) 2008-06-11

Family

ID=37110373

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800212085A Pending CN101198596A (zh) 2005-04-14 2006-04-14 作为hsp90抑制剂用于治疗增殖疾病的2-氨基-喹唑啉-5-酮

Country Status (12)

Country Link
US (1) US20070027150A1 (enExample)
EP (1) EP1885701A2 (enExample)
JP (1) JP2008536867A (enExample)
KR (1) KR20080006614A (enExample)
CN (1) CN101198596A (enExample)
AU (1) AU2006236557A1 (enExample)
BR (1) BRPI0609309A2 (enExample)
CA (1) CA2604942A1 (enExample)
MX (1) MX2007012836A (enExample)
RU (1) RU2007142007A (enExample)
TW (1) TW200718689A (enExample)
WO (1) WO2006113498A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101735119B (zh) * 2009-12-12 2013-03-27 浙江工业大学 一种三酮类化合物的合成方法
CN103333123A (zh) * 2013-07-17 2013-10-02 温州医学院附属第二医院 一种二氢喹唑啉酮化合物的脱卤方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
AU2007296745B2 (en) 2006-09-11 2011-12-01 Curis, Inc. Quinazoline based EGFR inhibitors
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CN101225083A (zh) * 2007-01-16 2008-07-23 北京摩力克科技有限公司 四氢喹唑啉酮类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
WO2008132211A1 (en) * 2007-05-01 2008-11-06 Novartis Ag Amino-quinazolinone derivatives for use as radiotracers and imaging agents
CN101687798B (zh) * 2007-05-17 2012-08-15 金克斯医药品有限公司 制备用于调节激酶级联的组合物的过程及其使用方法
GB2449293A (en) * 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
TW200920357A (en) * 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
ES2526718T3 (es) 2007-09-10 2015-01-14 Curis, Inc. Inhibidores de EGFR basados en sales de tartrato o complejos de quinazolina que contienen un resto que se une al cinc
TW200922595A (en) * 2007-10-12 2009-06-01 Novartis Ag Organic compounds
US20110111396A1 (en) * 2007-12-07 2011-05-12 Schafer Peter H Biomarkers for monitoring the treatment by quinazolinone compounds
WO2009097578A1 (en) * 2008-02-01 2009-08-06 Takeda Pharmaceutical Company Limited Oxim derivatives as hsp90 inhibitors
LT5623B (lt) 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
WO2010042489A2 (en) * 2008-10-06 2010-04-15 Emory University Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
DE102008061214A1 (de) 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US8481459B2 (en) * 2010-06-14 2013-07-09 Academia Sinica Chemical inhibitors of ethylene biosynthesis
ITTO20111013A1 (it) 2011-11-03 2013-05-04 Dac Srl Composti farmaceutici
US9348490B2 (en) * 2012-09-14 2016-05-24 Ca, Inc. User interface with configuration, registration, and runtime selection of views
EP3270814B1 (en) * 2015-03-17 2020-02-26 Intuitive Surgical Operations, Inc. Systems and methods for rendering onscreen identification of instruments in a teleoperational medical system
EP3459939A1 (en) * 2017-09-26 2019-03-27 Pragma Therapeutics Novel heterocyclic compounds as modulators of mglur7

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4723115B2 (ja) * 2001-05-23 2011-07-13 日本化薬株式会社 アデニル酸シクラーゼ５型阻害剤
US20050009817A1 (en) * 2003-04-30 2005-01-13 Jennifer Savoy Substituted heteroaryls
ES2339862T3 (es) * 2003-06-20 2010-05-26 Novartis Vaccines And Diagnostics, Inc. Compuestos de piridino 1,2-a-pirimidin-4-ona como agentes anticancerosos.
NZ546611A (en) * 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
PE20060572A1 (es) * 2004-07-27 2006-06-27 Novartis Ag Compuestos de benzoimidazolona como inhibidores de hsp90
AU2005266494B2 (en) * 2004-07-27 2009-09-10 Novartis Ag Inhibitors of Hsp90

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101735119B (zh) * 2009-12-12 2013-03-27 浙江工业大学 一种三酮类化合物的合成方法
CN103333123A (zh) * 2013-07-17 2013-10-02 温州医学院附属第二医院 一种二氢喹唑啉酮化合物的脱卤方法
CN103333123B (zh) * 2013-07-17 2015-03-11 温州医科大学附属第二医院 一种二氢喹唑啉酮化合物的脱卤方法

Also Published As

Publication number Publication date
AU2006236557A1 (en) 2006-10-26
CA2604942A1 (en) 2006-10-26
US20070027150A1 (en) 2007-02-01
BRPI0609309A2 (pt) 2010-03-09
WO2006113498A2 (en) 2006-10-26
EP1885701A2 (en) 2008-02-13
TW200718689A (en) 2007-05-16
MX2007012836A (es) 2008-01-11
JP2008536867A (ja) 2008-09-11
KR20080006614A (ko) 2008-01-16
RU2007142007A (ru) 2009-05-20
WO2006113498A3 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
US20070027150A1 (en) 2-Amino-quinazolin-5-ones
JP5036002B2 (ja) ２−アミノ−７，８−ジヒドロ−６Ｈ−ピリド［４，３−ｄ］ピリミジン−５−オン
CA2583907C (en) Heteroaryl-substituted alkyne compounds and method of use
CN100418971C (zh) 作为抗癌剂的杂芳基-稠合的嘧啶基化合物
CN102573473B (zh) 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物
TW200817359A (en) Chemical compounds
CN105669564B (zh) 脲类化合物、其制备方法、药物组合物、中间体及其应用
CA2586271C (en) Anthranilamide pyridinureas as vascular endothelial growth factor (vegf)receptor kinase inhibitors
CN101805309A (zh) 用作组蛋白脱乙酰基酶抑制剂的苯甲酰胺衍生物
JP2009532450A (ja) 化合物
CN116987066A (zh) 一种嘧啶类化合物及其制备方法和应用
JP5069119B2 (ja) 血管内皮成長因子（ｖｅｇｆ）受容体キナーゼインヒビターとしてのニコチンアミドピリジンウレア
CN117653636A (zh) 含稠合双环类化合物的抗癌药及该化合物的制药用途
CN101287734B (zh) 2-氨基-7,8-二氢-6H-吡啶并[4,3-d]嘧啶-5-酮
JP2009539993A (ja) プロテインキナーゼ阻害剤としての置換シアノピリジン
HK1122275A (en) 2-amino-quinazolin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
CN118772111A (zh) 一种取代的氨基嘧啶类化合物、药物组合物及其用途
HK1118823B (en) 2-amino-7,8-dihydro-6h-pyrido(4,3-d)pyrimidin-5-ones, process for their preparation and pharmaceutical compositions containing the same
HK1123801A (zh) 2-氨基-7，8-二氢-6h-吡啶并[4，3-d]嘧啶-5-酮

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1122275

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080611

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1122275

Country of ref document: HK